Iomai Announces Interim Results From Phase 1 Study of Its Patch-Based Vaccine for Seasonal Influenza

Iomai Corporation today announced interim results from a Phase 1 clinical trial of its patch-based vaccine for seasonal influenza.

GAITHERSBURG, MD, USA | May 25, 2007 |
Iomai Corporation (Nasdaq: IOMI) today announced interim results from a Phase 1 clinical trial of its patch-based vaccine for seasonal influenza.

The 353-patient study compared the immune responses generated by Iomai's needle-free vaccine patch and an injected intramuscular vaccine. Both vaccines contained the same three flu antigens. The trial showed that Iomai's vaccine patch stimulated an immune response to each of the three antigens in a dose-dependent manner. However, results show that the injected vaccine prompted a greater immune response compared with the patch vaccine. The Iomai patch was well tolerated at all dose levels, consistent with previous safety data from other Iomai patch studies.

"This Phase 1 trial has shown that we can deliver all three large flu antigens into the skin and to the immune system with our dry patch formulation," said Dr. Gregory Glenn, M.D., the Founder and Chief Scientific Officer of Iomai. "Both the Iomai patch and the injected vaccine used a type of antigen known as split-virus. While split-virus is the traditional approach for injected flu vaccines, such antigens may not be best suited for patch application. There are a number of alternatives being tested that we believe hold great promise."

The study also demonstrated that adding Iomai's immune-boosting adjuvant, known as LT, to the influenza antigens improved response to the patch vaccine. This finding will assist in the design of future trials in Iomai's needle-free influenza program.

"The efficient delivery of adjuvant seen in this trial is consistent with success in Iomai's other programs, including booster patches for seasonal and pandemic influenza," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "We believe this is a confirmation of our transcutaneous immunization, or TCI, technology, which makes patch-based, needle-free vaccine possible."

Iomai's needle-free approach to vaccination could have several potential benefits versus injectable vaccines. The patch formulations are stable at room temperature and the process of vaccination is designed so that a patch can be self-applied.

Conference Call Details

To access the live conference call today at 8:30 a.m. Eastern Time via phone, please dial 888-396-2356 from the United States and Canada or 617-847-8709 internationally. The conference ID is 63780500. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through June 1, 2007 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 75528925.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at . Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (, a password-protected event management site.

About Iomai Corporation

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea. For more information on Iomai, please visit

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the ability of Iomai to make a commercial patch-based, needle-free vaccine; the use of these results to design future studies of Iomai's vaccine candidates for needle-free flu vaccines and conducting such studies; the potential attributes of an Iomai vaccine patch; and the potential for alternative influenza antigens. Applicable risks and uncertainties include, among others, that the clinical results described in this press release may not provide the needed information necessary to design future studies; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials; that results in future clinical trials may fail to demonstrate our patch vaccines can be self-applied; that results from future stability studies may fail to demonstrate the stability of needle-free patches at room temperature; that alternative influenza antigens may not perform better in future studies in our TCI system; that development costs may exceed expectations; that Iomai may lack sufficient financial resources to fund its programs; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified under the heading "Factors That May Impact Future Results" in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Quarterly Report on Form 10-Q for the three months ended March 31, 2007, and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company's filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at

These statements speak only as of the date of this document, and Iomai undertakes no obligation to update or revise the statements.

SOURCE: Iomai Corporation

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up